These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 12563663)

  • 1. Determining the optimal combinations of mutually exclusive interventions: a response to Hutubessy and colleagues.
    Coyle D
    Health Econ; 2003 Feb; 12(2):159-62; discussion 163-4. PubMed ID: 12563663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stochastic league tables: communicating cost-effectiveness results to decision-makers.
    Hutubessy RC; Baltussen RM; Evans DB; Barendregt JJ; Murray CJ
    Health Econ; 2001 Jul; 10(5):473-7. PubMed ID: 11466807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uncertainty in cost-effectiveness analysis. Probabilistic uncertainty analysis and stochastic league tables.
    Baltussen RM; Hutubessy RC; Evans DB; Murray CJ
    Int J Technol Assess Health Care; 2002; 18(1):112-9. PubMed ID: 11987434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stochastic league tables: an application to diabetes interventions in the Netherlands.
    Hutubessy RC; Niessen LW; Dijkstra RF; Casparie TF; Rutten FF
    Health Econ; 2005 May; 14(5):445-55. PubMed ID: 15386648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda.
    Gafni A; Birch S
    Soc Sci Med; 2006 May; 62(9):2091-100. PubMed ID: 16325975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
    Adang E; Voordijk L; Jan van der Wilt G; Ament A
    Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the value for money of changing clinical practice change: a stochastic application in diabetes care.
    Hoomans T; Abrams KR; Ament AJ; Evers SM; Severens JL
    Med Care; 2009 Oct; 47(10):1053-61. PubMed ID: 19648827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decision makers' views on health care objectives and budget constraints: results from a pilot study.
    Al MJ; Feenstra T; Brouwer WB
    Health Policy; 2004 Oct; 70(1):33-48. PubMed ID: 15312708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finding legitimacy for the role of budget impact in drug reimbursement decisions.
    Niezen MG; de Bont A; Busschbach JJ; Cohen JP; Stolk EA
    Int J Technol Assess Health Care; 2009 Jan; 25(1):49-55. PubMed ID: 19126251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Priority setting in practice: what is the best way to compare costs and benefits?
    Wilson EC; Peacock SJ; Ruta D
    Health Econ; 2009 Apr; 18(4):467-78. PubMed ID: 18561215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reliability analysis based on the losses from failures.
    Todinov MT
    Risk Anal; 2006 Apr; 26(2):311-35. PubMed ID: 16573623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generalised cost-effectiveness analysis: an aid to decision making in health.
    Hutubessy RC; Baltussen RM; Torres-Edejer TT; Evans DB
    Appl Health Econ Health Policy; 2002; 1(2):89-95. PubMed ID: 14619255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expected value of information and decision making in HTA.
    Eckermann S; Willan AR
    Health Econ; 2007 Feb; 16(2):195-209. PubMed ID: 16981193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold.
    Birch S; Gafni A
    J Health Serv Res Policy; 2006 Jan; 11(1):46-51. PubMed ID: 16378532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Portfolio theory and the alternative decision rule of cost-effectiveness analysis: theoretical and practical considerations.
    Sendi P; Al MJ; Gafni A; Birch S
    Soc Sci Med; 2004 May; 58(10):1853-5. PubMed ID: 15020003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of hearing aids in the hearing-impaired elderly: a probabilistic approach.
    Chao TK; Chen TH
    Otol Neurotol; 2008 Sep; 29(6):776-83. PubMed ID: 18725859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs.
    Jeuland M; Whittington D
    Vaccine; 2009 May; 27(23):3109-20. PubMed ID: 19428925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Portfolio evaluation of health programs: a reply to Sendi et al.
    Bridges JF; Terris DD
    Soc Sci Med; 2004 May; 58(10):1849-51. PubMed ID: 15020002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The option value of delay in health technology assessment.
    Eckermann S; Willan AR
    Med Decis Making; 2008; 28(3):300-5. PubMed ID: 18480035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA.
    O'Hagan A; Stevenson M; Madan J
    Health Econ; 2007 Oct; 16(10):1009-23. PubMed ID: 17173339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.